Skip to main content

Rich Law

Analyst

Goldman Sachs

Equibles does not estimate personal net worth.

About Rich Law

Rich Law is recorded as Analyst at Goldman Sachs. Rich Law has spoken on 3 earnings calls across 3 companies, most recently for Hemab Therapeutics Holdings, Inc. on November 10, 2026. Those appearances were for Hemab Therapeutics Holdings, Inc. (COAG), Mineralys Therapeutics, Inc. (MLYS) and Crinetics Pharmaceuticals, Inc.. The companies whose calls Rich Law spoke on are classified in the Healthcare sector.

Rich Law on recent calls

“So I'm actually kind of surprised that the FDA asked for the randomized control trial since we saw many pivotal trials in Hime and VWD using single-arm trials that you pointed out.”
Analyst — Goldman Sachs, Hemab Therapeutics Third Quarter 2026 Financial Results and Corporate Update ·
“So, when you look at the results from the Phase 2 OSA study, do you think the desired limited laryngeal has potential to show benefit in the AGI primary endpoint?”
Analyst — Goldman Sachs, Mineralys Therapeutics, Inc. Q4 FY2025 Earnings Call ·
“How much do you think you can learn based on Atumelan's cohort with only 10 patients? And I assume there's going to be data variability. Is there a chance to adjust the phase three protocol based on what you learn in that cohort for since you're starting the phase three study before you see the phase two data?”
Analyst — Goldman Sachs, Crinetics Pharmaceuticals, Inc. Q2 FY2025 Earnings Call ·

Affiliation history

  • Goldman Sachs

    Analyst

    Transcript header (unverified)

    Current

Company network

Crinetics Pharmaceuticals, Inc.

Biotechnology · Healthcare

1 appearance Latest appearance 2025-08-07

Recent activity